Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Down 12.7% in January

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 50,692 shares, a decline of 12.7% from the January 15th total of 58,049 shares. Based on an average daily volume of 70,257 shares, the short-interest ratio is currently 0.7 days. Currently, 0.6% of the shares of the company are short sold. Currently, 0.6% of the shares of the company are short sold. Based on an average daily volume of 70,257 shares, the short-interest ratio is currently 0.7 days.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. acquired a new position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals at the end of the most recent reporting period. 28.40% of the stock is currently owned by hedge funds and other institutional investors.

Anebulo Pharmaceuticals Price Performance

Shares of ANEB opened at $0.49 on Thursday. The firm has a market capitalization of $19.95 million, a P/E ratio of -2.57 and a beta of -0.81. Anebulo Pharmaceuticals has a one year low of $0.44 and a one year high of $3.42. The business has a fifty day moving average of $1.14 and a 200 day moving average of $1.99.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last announced its earnings results on Friday, February 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.08. Analysts expect that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.